Probenecid Dose in Gout and Other Indications

Probenecid inhibits the reabsorption of uric acid in the proximal convoluted tubules of the kidneys resulting in the excess excretion of uric acid.

Probenecid Uses:

  • It is indicated for the management of hyperuricemia due to gout, gouty arthritis, prolongation and elevation of beta-lactam plasma levels.

Guideline recommendations:

  • Gout:

    • Probenecid is a uricosuric drug that is prescribed alone or concurrently with allopurinol in patients without proper control with allopurinol alone.
  • Off Label Use of Probenecid in Adults:

    • Neurosyphilis including ocular syphilis
    • Pelvic inflammatory disease

Probenecid dosage in adults:

Probenecid Dose for the treatment of Hyperuricemia with gout:

  • 250 mg twice daily per oral for 7 days.
  • It can be increased to 500 mg twice daily.
  • If needed it can be increased to a maximum of 2 g/day (increase dosage in 500 mg increments every one month).
  • If serum uric acid levels become normal and there are no gout attacks for 6 months, daily dosage may be reduced by 500 mg every 6 months.

Probenecid Dosage for prolonging serum penicillin levels:

  • 500 mg per oral 4 times a day.

Probenecid dose for the treatment of Neurosyphilis, including ocular syphilis, as an alternative to the preferred therapy:

  • 500 mg per oral 4 times/day in combination with procaine penicillin intramuscular for 10 to 14 days.

Probenecid dose for the treatment of Pelvic inflammatory disease:

  • 1 g as a single dose per oral in addition to cefoxitin intramuscular as a single dose plus oral doxycycline (with/ without oral metronidazole) for 2 weeks.

Probenicid dosage in children:

Probenecid dose to prolong serum penicillin levels:

  • Children ≥2 years and Adolescents:

Note: Dosing for some indication-specific dosing may vary.

  • Patient weight ≤50 kg:

    • Initial dose of 25 mg/kg per oral  or 700 mg/m  as a single dose
    • maintenance: 40 mg/kg per oral per day or 1,200 mg /m /day in 4 divided doses
    • maximum dose: 500 mg.
  • Patient weight >50 kg:

    • 500 mg per oral 4 times daily.

Probenecid dose for the treatment of Gonorrhea and uncomplicated infections of cervix, urethra, and rectum:

  • Adolescents >45 kg:

    • 1,000 mg as a single dose per oral in addition with cefoxitin
    • Note: A combination of ceftriaxone plus azithromycin is preferred.

Probenecid dose for the treatment of Pelvic inflammatory disease in Adolescents:

  • 1,000 mg per oral as a single dose with cefoxitin and doxycycline with/without metronidazole.

Probenecid dose for the treatment of Neurosyphilis in Adolescents:

  • 500 mg per oral 4 times daily with procaine penicillin for 10 to 14 days as an alternative therapy to aqueous penicillin G therapy.

Probenecid Dose in the prevention of Cidofovir nephrotoxicity:

Note: The manufacturer's labeling considers use in patients <2 years of age is contraindicated, however, clinical studies have included younger ages including infants for this indication.

  • Weight-based dosing:

    • 25 to 40 mg/kg/dose per oral (maximum dose: 2,000 mg) administered 3 hours before cidofovir infusion and 10 to 20 mg/kg/dose (maximum dose: 1,000 mg) at 2 to 3 hours and 8 to 9 hours after cidofovir infusion.
  • BSA-based dosing:

    • 1,000 or 1,250 mg/m²/dose per oral given 3 hours prior to cidofovir, followed by 500 to 1,250 mg/m² /dose 1 to 2 hours and 8 hours after completion.

Probenecid Pregnancy Risk Category: B

  • Probenecid can cross the placenta.
  • According to available data, there is no evidence of an increase in the risk of adverse fetal outcomes.
  • Breastmilk may contain small amounts of the drug.

Probenicid dose adjustment in renal disease:

  • Glomerular filtration rate <30 mL/minute:

    • It should not be prescribed(reduced efficacy with renal impairment)

Note: Probenecid is not prescibed as first-line urate-lowering single agent in patients with renal impairment (CrCl <50 mL/minute).

Probenecid dose adjustment in liver disease:

There are no dosage adjustments provided in the manufacturer’s labeling.

Side effects of Probenecid:

  • Cardiovascular:

    • Flushing
  • Central Nervous System:

    • Dizziness
    • Headache
    • Pain (Costovertebral)
  • Dermatologic:

    • Alopecia
    • Dermatitis
    • Pruritus
    • Skin Rash
  • Endocrine & Metabolic:

    • Acute Gouty Arthritis
  • Gastrointestinal:

    • Anorexia
    • Dyspepsia
    • Gastroesophageal Reflux Disease
    • Gingival Pain
    • Nausea
    • Vomiting
  • Genitourinary:

    • Hematuria
    • Nephrotic Syndrome
  • Hematologic & Oncologic:

    • Anemia
    • Aplastic Anemia
    • Hemolytic Anemia (In G6PD Deficiency)
    • Leukopenia
  • Hepatic:

    • Hepatic Necrosis
  • Hypersensitivity:

    • Anaphylaxis
    • Hypersensitivity Reaction
  • Renal:

    • Polyuria
    • Renal Colic
  • Miscellaneous:

    • Fever

Contraindication to Probenecid:

  • Hypersensitivity reactions to the drug, or any component thereof, are contraindications.
  • Aspirin therapy
  • blood dyscrasias
  • Urin acid renal calculus
  • Children under 2 years old
  • Gout attacks that are severe

Warnings and precautions

  • Allergy reaction:

    • Although severe hypersensitivity reactions, including anaphylaxis, are rare, it is important to discontinue therapy if they occur.
  • Gout

    • Could cause acute gout inflammation.
  • G6PD deficiency:

    • Patients with G6PD deficiency should be cautious as this can increase the risk of hemolytic anemia.
  • Peptic ulcer disease:

    • Patients with peptic ulcer disease should be cautious.
  • Renal impairment

    • A creatinine clearance of 30mL/minute is ineffective for single-agent.
    • According to the American College of Rheumatology Guidelines for Hyperuricemia Treatment, probenecid is not recommended as a first-line or alternative therapy for patients with creatinine clearances below 50 mL/minute.

Probenecid: Drug Interaction

Note: Drug Interaction Categories:

  • Risk Factor C: Monitor When Using Combination
  • Risk Factor D: Consider Treatment Modification
  • Risk Factor X: Avoid Concomitant Use

Risk Factor C (Monitor therapy)

Anagliptin Probenecid may increase the serum concentration of Anagliptin.
Cabozantinib MRP2 Inhibitors may increase the serum concentration of Cabozantinib.
Cephalosporins Probenecid may increase the serum concentration of Cephalosporins.
Dapsone (Systemic) Probenecid may increase the serum concentration of Dapsone (Systemic).
Dexketoprofen Probenecid may increase the serum concentration of Dexketoprofen.
Ertapenem Probenecid may increase the serum concentration of Ertapenem.
Ganciclovir-Valganciclovir Probenecid may increase the serum concentration of GanciclovirValganciclovir.
Gemifloxacin Probenecid may increase the serum concentration of Gemifloxacin.
Imipenem Probenecid may increase the serum concentration of Imipenem.
Ketoprofen Probenecid may increase the serum concentration of Ketoprofen.
Loop Diuretics Probenecid may enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics. Management: Monitor for decreased diuretic effects or increased adverse effects of loop diuretics with concomitant use of probenecid. Bumetanide prescribing information recommends against concomitant use of probenecid.
Minoxidil (Systemic) Probenecid may increase the serum concentration of Minoxidil (Systemic).
Mycophenolate Probenecid may increase the serum concentration of Mycophenolate.
Nitrofurantoin Probenecid may increase the serum concentration of Nitrofurantoin.
Nonsteroidal Anti-Inflammatory Agents Probenecid may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.
Penicillins Probenecid may increase the serum concentration of Penicillins.
PRALAtrexate Probenecid may increase the serum concentration of PRALAtrexate.
Quinolones Probenecid may decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones. Exceptions: Moxifloxacin (Systemic).
Salicylates May diminish the therapeutic effect of Probenecid.
Sodium Benzoate Probenecid may increase the serum concentration of Sodium Benzoate. Specifically, probenecid may inhibit the renal transport of the hippuric acid metabolite of sodium benzoate.
Sodium Phenylacetate Probenecid may increase the serum concentration of Sodium Phenylacetate. Specifically, probenecid may inhibit the renal transport of the phenylacetylglutamine metabolite of sodium phenylacetate.
Sulfonylureas Probenecid may decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.
Theophylline Derivatives Probenecid may increase the serum concentration of Theophylline Derivatives. Exceptions: Aminophylline; Theophylline.
Urea Cycle Disorder Agents Probenecid may increase serum concentrations of the active metabolite(s) of Urea Cycle Disorder Agents. Specifically, concentrations of phenylacetate and phenylacetylglutamine may be increased.
Zidovudine Probenecid may decrease the metabolism of Zidovudine.

Risk Factor D (Consider therapy modification)

Acetaminophen Probenecid may increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.
Betalactamase Inhibitors Probenecid may increase the serum concentration of Betalactamase Inhibitors. Management: Coadministration of probenecid with amoxicillin/clavulanate is not recommended per official package labeling. Exceptions: Avibactam; Sulbactam.
Cefotaxime Probenecid may increase the serum concentration of Cefotaxime. Management: Avoid cefotaxime doses greater than 6 g/day with concurrent probenecid. Any patients receiving this combination should be monitored closely for evidence of cefotaxime toxicity.
LORazepam Probenecid may increase the serum concentration of LORazepam.
Methotrexate Probenecid may increase the serum concentration of Methotrexate. Management: Avoid concomitant use of probenecid and methotrexate if possible. If used together, consider lower methotrexate doses and monitor for evidence of methotrexate toxicity.
Oseltamivir Probenecid may increase serum concentrations of the active metabolite(s) of Oseltamivir. Management: Consider a change in therapy when using oseltamivir together with probenecid; reduced oseltamivir dose may be necessary. Increase monitoring for adverse events, such as thrombocytopenia.
Pexidartinib UGT1A6 Inhibitors may increase the serum concentration of Pexidartinib. Management: Avoid use of UGT1A6 inhibitors and pexidartinib. If combined use is required, reduce the pexidartinib dose. If receving pexidartinib 800 mg or 600 mg daily, reduce to 200 mg twice daily. If receiving 400 mg/day, reduce to 200 mg/day.
Propacetamol Probenecid may increase serum concentrations of the active metabolite(s) of Propacetamol. Specifically, accetaminophen exposure may be increased. Probenecid may also limit the formation of at least one major non-toxic acetaminophen metabolite, possibly increasing the formation of the toxic NAPQI metabolite. Management: Consider limiting the use of propacetamide in patients who are also taking probenecid. Patients may be at an increased risk for toxicity, even if reduced propacetamide doses are used.

Risk Factor X (Avoid combination)

Avibactam Probenecid may increase the serum concentration of Avibactam.
Baricitinib Probenecid may increase the serum concentration of Baricitinib.
Deferiprone UGT1A6 Inhibitors may increase the serum concentration of Deferiprone.
Doripenem Probenecid may increase the serum concentration of Doripenem. This effect is due to probenecid's ability to decrease the active tubular secretion of doripenem.
Ketorolac (Nasal) Probenecid may increase the serum concentration of Ketorolac (Nasal).
Ketorolac (Systemic) Probenecid may increase the serum concentration of Ketorolac (Systemic).
Meropenem Probenecid may increase the serum concentration of Meropenem.
Pegloticase Probenecid may enhance the adverse/toxic effect of Pegloticase. Specifically, Probenecid may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions.

Monitoring parameters:

Different parameters including serum and urine uric acid, renal function, complete blood count, and frequency of gout attacks should be monitored.

How to administer Probenecid?

It should be administered with food to avoid gastrointestinal effects.

Mechanism of action of Probenecid:

  • It causes competitive inhibition of the reabsorption uric acids at the proximal convoluted tubeule, leading to an increase in excretion and a decrease in serum uric Acid level.
  • This causes an increase in plasma levels of weak organic acids, such as penicillins and cephalosporins or other beta-lactam antibiotics, by competitively inhibiting the secretion of renal tubules

The onset of action:

  • Effect on penicillin levels: 120 minutes;
  • Uric acid renal clearance: 30 minutes

Absorption:

  • Rapid and complete

Protein binding:

  • 85% to 95%

Metabolism:

  • Occurs in liver

Half-life elimination (dose-dependent):

  • Normal renal function: 6 to 12 hours

The time to reach peak serum concentration:

  • 2 to 4 hours

Excretion:

  • occurs in urine

Probenecid Brand Names (International): 

  • Benuryl
  • Benacid
  • Bencid
  • Benecid Valdecasas
  • Benemid
  • Benemide
  • Benuryl
  • Brocid
  • Gonocilin
  • Pro-Cid
  • Probecid
  • Probecilin
  • Probenecid Weimer
  • Probenecid ”Dak”
  • Probenecid ”Medic”
  • Procid
  • Pronid
  • Santuril
  • Uri-Forte

Probenecid Brand Names in Pakistan:

No Brands Available in Pakistan.

Comments

NO Comments Found